These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29165283)

  • 21. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer.
    Sacco PC; Maione P; Guida C; Gridelli C
    Curr Clin Pharmacol; 2017; 12(1):4-10. PubMed ID: 27908252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.
    Dovedi SJ; Cheadle EJ; Popple AL; Poon E; Morrow M; Stewart R; Yusko EC; Sanders CM; Vignali M; Emerson RO; Robins HS; Wilkinson RW; Honeychurch J; Illidge TM
    Clin Cancer Res; 2017 Sep; 23(18):5514-5526. PubMed ID: 28533222
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.
    Liu C; Wu S; Meng X; Liu G; Chen D; Cong Y; Shen G; Sun B; Wang W; Wang Q; Gao H; Liu X
    Oncotarget; 2017 Jun; 8(26):43427-43438. PubMed ID: 28624781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-reprogrammed resident T cells resist radiation to control tumors.
    Arina A; Beckett M; Fernandez C; Zheng W; Pitroda S; Chmura SJ; Luke JJ; Forde M; Hou Y; Burnette B; Mauceri H; Lowy I; Sims T; Khodarev N; Fu YX; Weichselbaum RR
    Nat Commun; 2019 Sep; 10(1):3959. PubMed ID: 31477729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
    Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
    Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
    Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
    Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving efficacy of cancer immunotherapy through targeting of macrophages.
    Peranzoni E; Donnadieu E
    Hum Vaccin Immunother; 2019; 15(1):189-192. PubMed ID: 30192699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Precision medicine and immuno-radiotherapy].
    Chargari C; Robert C; Genestie C; Deutsch E
    Cancer Radiother; 2021 Oct; 25(6-7):570-575. PubMed ID: 34391650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.
    Ajona D; Ortiz-Espinosa S; Moreno H; Lozano T; Pajares MJ; Agorreta J; Bértolo C; Lasarte JJ; Vicent S; Hoehlig K; Vater A; Lecanda F; Montuenga LM; Pio R
    Cancer Discov; 2017 Jul; 7(7):694-703. PubMed ID: 28288993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
    Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
    Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
    Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
    Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
    Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expansion of Tumor-Infiltrating CD8
    Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
    Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.